reason report
exparel meet expect lt growth vision ambiti
bottom line manag deliv exparel expect
need y/i growth reach midpoint
guidanc account look achiev given five
consecut quarter growth remain question
exparel averag least high teen y/i growth
forese futur street includ us appear
skeptic start con potenti
launch iovera manag continu exud greater
confid opportun take cautious
optimist view continu mp maintain pt
watch posit trend support manag longer-
confid exparel growth quarter manag point
final rule ad tka list procedur medicar
histor trend suggest procedur medicar patient
manag also note continu incent conduct procedur
set exampl unitedhealthcar site-of-servic polici
requir prior author pa medic necess differ
procedur direct asc rather outpati set
collabor op also expect continu drive
exparel use manag reiter confid hit
exparel guidanc
number exparel clinic program expect progress
near term studi expect readout ye
could support snda exparel pediatr popul result
phase choic studi c-section expect januari
nerv block lower extrem expect start soon
fusion studi compar exparel multimod regimen standard
care spine surgeri enrol patient manag continu
work fda defin phase nerv block studi pediatr
chmp opinion expect
anoth step manag expect iovera
manag note expect annual iovera sale approach
within next year indic
earn call manag point improv medicar
reimburs outpati set increas total reimburs
nearli iovera procedur target genicular
nerv around knee
dcf use wacc
termin growth rate
net debt total capit
per share net cash includ short-
term long-term invest
year price history/av daili volume mil
compani inform svb leerink llc research
revenu
pleas refer page import disclosur price chart analyst certif
target patient focu two group first provid iovera
exparel combo solut tka second target oa patient seek
activ lifestyl drug-fre opioid-fre surgery-fre pain
sever month regard manufactur manag expect
abl suppli smart tip signific
increas prior owner never made
smart tip given year
chang model rais exparel sale get
midpoint guidanc see y/i growth
achiev increas gross margin slightli base
move sg spend low end guidanc note could see
number come guidanc rang
ep increas exparel
sale go slightli lead posit ep impact
year margin impact valuat henc pt
remain
believ pacira exparel non-opioid post-op pain manag
continu grow driven commerci collabor unbundl
sale believ long-term growth may impact
entri heron better clinic profil -- longer durat pain relief hour
vs hour easier administr instil vs infiltr base medacorp
survey believ posit tailwind unbundl set gradual
could increas time initi analysi suggest competit impact
temper impact rate pacira stock market perform mp price target
pt base dcf forecast cash flow use
wacc termin growth rate
phase iv studi success limit impact collabor potenti competit
heron iovera may gain much adopt due econom
note number
figur chang model
svb leerink estim note number except ep
note revenu
changevalu changevarianceconsensusactu vs constherapeut product licens mileston basic dilut non-gaap adjustmentstot one-tim net pacira bioscienc inc
brand
type event
event trial detail
date known
up/down
view
top-lin result studi
cardiovasular spine surgeri
top-lin result opioid-fre c-
svb leerink llc equiti research compani file
number except per share data
net debt ebitda ratio
figur except per share data
collabor licens develop revenu
sourc press releas transcript sec file
number except per share data
prepaid expens
current portion defrer revenu
accumul comprehens loss
number except per share data
adjust reconcil ni net cash oper
amort unfavor leas oblig debt issuanc cost
amort debt discount
loss dispos fix asset
loss extinguish debt
decreas increas work capit
purchas fix asset capital-expenditure
purchas invest
sale invest
payment conting consider
net invest
proce exercis stock option warrant
proce share issu employe stock purchas plan
convers princip equiti compon convert senior
net financ
net chang equival
